Advertisement
Advertisement
U.S. markets open in 2 hours 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Encision Inc. (ECIA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.55000.0000 (0.00%)
At close: 01:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5500
Open0.5910
BidN/A x N/A
AskN/A x N/A
Day's Range0.5500 - 0.5500
52 Week Range0.4500 - 1.5000
Volume17,266
Avg. Volume3,264
Market Cap6.446M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateMay 19, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 13, 1996
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ECIA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ENCISION INC
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • ACCESSWIRE

    Encision Reports Fourth Quarter Fiscal Year 2022 Results

    BOULDER, CO / ACCESSWIRE / June 16, 2022 / Encision Inc. (OTCPK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2022 fourth quarter that ended March 31, 2022.

  • ACCESSWIRE

    Encision Reports Third Quarter Fiscal Year 2022 Results

    BOULDER, CO / ACCESSWIRE / February 10, 2022 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2022 third quarter that ended December 31, 2021.

  • PR Newswire

    Encision Reports Second Quarter Fiscal Year 2022 Results

    Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2022 second quarter that ended September 30, 2021.

Advertisement
Advertisement